The positive opinion recommends grant of a conditional marketing authorization. The revised positive opinion has been issued following review by the CHMP of new data received in February 2008 from GSK arising from a standard pharmacovigilance evaluation of clinical trial and post-marketing data.1 The CHMP has confirmed that these data do not essentially change the positive benefit-risk profile for lapatinib in its proposed indication.
Upon grant of the conditional marketing authorization by the European Commission, lapatinib, in combination with capecitabine, will be indicated for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress ErbB2 (HER2).